166816-11-1 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule of the compound.
Explanation
Describes the physical appearance of the compound in its solid state.
Explanation
The compound belongs to a group of chemically related substances derived from benzodioxin.
Explanation
The compound is utilized as a building block for the production of other chemicals in the field of organic chemistry.
Explanation
The compound may possess hazardous properties that require careful handling and usage.
Explanation
Due to its potential hazardous properties, it should be used and handled by trained professionals in a controlled environment to ensure safety.
Explanation
The color of the compound in its solid state, which can be an identifying characteristic.
Explanation
The physical state of the compound at room temperature and pressure.
Explanation
The compound is derived from the 1,4-benzodioxin structure, with specific modifications (e.g., chlorination and dihydro substitution).
Appearance
Yellow-brown solid
Chemical family
Benzodioxin derivatives
Usage
Organic synthesis and research
Hazardous properties
Potentially hazardous
Handling
Controlled environment and trained professionals
Color
Yellow-brown
State
Solid
Derivative
1,4-Benzodioxin-5-yl
Check Digit Verification of cas no
The CAS Registry Mumber 166816-11-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,6,8,1 and 6 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 166816-11:
(8*1)+(7*6)+(6*6)+(5*8)+(4*1)+(3*6)+(2*1)+(1*1)=151
151 % 10 = 1
So 166816-11-1 is a valid CAS Registry Number.
166816-11-1Relevant articles and documents
Process development of the synthetic route to sulamserod hydrochloride
Kowalczyk, Bruce A.,Robinson III, James,Gardner, John O.
, p. 116 - 121 (2001)
Sulamserod hydrochloride is a potent S-HT4 receptor antagonist and was a clinical candidate for the treatment of gastrointestinal disorders. Process development of the fairly long synthetic route (12 linear, 14 overall steps) was undertaken. Process improvements were highlighted by aromatic chlorination choices in making dichlorobenzodioxan 2 and acetylaminochloroketone 7, a transfer hydrogenation reducing a nitro group and simultaneous aromatic dechlorination without ketone reduction to give aminoketone 5, and use of the potential mutagenic iodosulfonamide 14 to make quaternary salt 11. The chemistry was scaled-up into pilot plant reactor vessels to produce multikilogram amounts of Sulamserod hydrochloride suitable for drug development.
